Tech Company Financing Transactions
Alkeus Pharmaceuticals Funding Round
On 6/5/2023, Alkeus Pharmaceuticals raised $150 million in Series B financing from Bain Capital Life Sciences, Sofinnova Ventures and Wellington Management Company.
Transaction Overview
Company Name
Announced On
6/5/2023
Transaction Type
Venture Equity
Amount
$150,000,000
Round
Series B
Investors
Proceeds Purpose
Alkeus Pharmaceuticals, a Cambridge, Mass.-based biotech focused on treating a genetic cause of blindness.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2464 Massachusetts Ave 314
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
Alkeus was co-founded by Leonide Saad, Ph.D. and Ilyas Washington, Ph.D. with the goal of treating degenerative eye diseases in a completely new way: developing a molecule that could reduce the potential for toxicity when vitamin A dimerizes --clumps --in the eye. This dimerization is a key underlying contributor to the irreversible retinal damage that is common to a number of eye diseases. Alkeus has steadily progressed its lead molecule gildeuretinol (ALK-001), demonstrating its tremendous promise and advancing a comprehensive clinical program.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Joshua Boger
Chief Executive Officer
Leonide Saad
Chief Operating Officer
David Setboun
Co-Founder
Ilyas Washington
Browse more venture capital transactions:
Prev: 6/5/2023: Ferretly venture capital transaction
Next: 6/5/2023: Impact Analytics venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs